Semaglutide Obesity Drug Reduces Alcohol Consumption by 50%, Study Finds.

A new study has found that Semaglutide, a drug used to treat obesity and diabetes, significantly reduced alcohol consumption and relapses in alcohol-dependent rats by blocking alcohol-induced dopamine release in the brain's reward system. Clinical studies on humans are needed to confirm these findings, but the medication may be of most benefit to patients suffering from both overweight and alcohol dependence. Semaglutide is a long-acting substance that only needs to be taken once a week and is the first medication to act on the GLP-1 receptor that can be taken in tablet form.